# PRISM BioLab Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prism-biolab-co

- Industry: Biotechnology
- Headquarters: Fujisawa-shi, Japan
- Website: www.prismbiolab.com
- Total disclosed funding: $12M
- Latest round: Series C (Sep 9, 2021)
- Investors on record: 13

## About

Established in 2006 and founded in Fujisawa, Japan, PRISM BioLab Co., Ltd. is a drug discovery company that focuses on developing small molecule technologies that modulate protein-protein interactions. In July 2024, PRISM BioLab Co., Ltd. raised JPY 1.8 billion in an IPO, selling 4 million shares at JPY 450 per share within the expected JPY 435-450 range, on the Tokyo Stock Exchange Growth Section. The listing values PRISM BioLab Co., Ltd. at JPY 15.91 billion.

The PRISM Library is designed to mimic a-helix or ß-turn peptide using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using our small molecule drug discovery technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed to Japanese Pharma companies. Many early lead molecules have also been created for novel or previously non-druggable targets.

In 2012, PRISM BioLab Corporation recently changed its name to PRISM Pharma Co., Ltd. and established a new subsidiary PRISM BioLab. However, in 2018, PRISM Pharma merged with PRISM BioLab, and PRISM BioLab Co., Ltd. continued its business as a surviving company and will succeed all rights and obligations of PRISM Pharma Co., Ltd. Over the years, PRISM BioLab has partnered with various companies such as Eisai, Riken, Boehringer Ingelheim, Inveni AI, Merck and Servier.

The company plans to use the funding raised in the IPO to pursue its business growth and development.

## Funding rounds

- Series C, Sep 9, 2021, $12M — Daiwa Corporate Investment, JAFCO Group, INCJ, Neostella Capital, WM Partners, Collabo SANGAKUKAN, DBJ Capital, Angel Capital, Newton Biocapital Partners, Ohara Pharmaceutical Co.,Ltd., Healthcare Innovation, Gemseki Inc.
- Series A, Dec 27, 2018 — Life Science Venture Capital

## Investors

- Life Science Venture Capital (https://capitalatlas.ai/funds/life-science-venture-capital) — Series A
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series C
- INCJ — Series C
- Neostella Capital (https://capitalatlas.ai/funds/neostella-capital) — Series C
- WM Partners — Series C
- Collabo SANGAKUKAN (https://capitalatlas.ai/funds/collabo-sangakukan) — Series C
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series C
- Angel Capital (https://capitalatlas.ai/funds/angel-capital) — Series C
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series C
- Ohara Pharmaceutical Co.,Ltd. — Series C
- Healthcare Innovation — Series C
- Gemseki Inc. — Series C